CCM
CYTK icon

Coldstream Capital Management’s Cytokinetics CYTK Stock Holding History

Coldstream Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$392K Buy
5,945
+625
+12% +$39.7K ﹤0.01% 832
2025
Q4 		$338K Buy
5,320
+568
+12% +$35.3K ﹤0.01% 861
2025
Q3 		$261K Buy
+4,752
New +$196K ﹤0.01% 1004
2025
Q2 		– Sell
-2,869
Closed -$115K – 1663
2025
Q1 		$115K Buy
+2,869
New +$132K ﹤0.01% 1275

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Coldstream Capital Management's CYTK Position: Q1 2026 in Review

Coldstream Capital Management increased its Cytokinetics (CYTK) stake by 12% in Q1 2026, buying an estimated $39.7K and bringing the position to 5,945 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #832.

Coldstream Capital Management first reported a position in CYTK in Q1 2025 and has held it in 4 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Coldstream Capital Management held 5,945 shares of Cytokinetics worth $392K as of Q1 2026.
  • Coldstream Capital Management bought 625 Cytokinetics shares in Q1 2026, an estimated $39.7K.
  • Cytokinetics made up ﹤0.01% of Coldstream Capital Management's portfolio in Q1 2026, its #832 holding.
  • Coldstream Capital Management first reported a position in Cytokinetics in Q1 2025 and has held it in 4 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.